29th December 2004
Thursday, September 2nd, 2010
Polfa Tarchomin aims to become leading producer of insulin
In January, Polfa Tarchomin will launch the production of human insulin and the company expects to become the fourth largest player on the domestic market which is worth zł.500 million.
The firm spent several million złoty to achieve this goal, "We have expanded our production line. We are currently producing 200-300 packages per hour, but the number will increase to 3,000 in January," said Polfa president Andrzej Kleszczewski. There are three big players present on the market - Eli Lilly, Novo Nordisk and domestic Bioton. "The market is large and it is still growing, so there is room for another producer. However, insulin is a special type of medicine and it is difficult to convince an ill person to switch to another brand," said Piotr Wielesik, deputy president of Bioton. Revenues of Polfa will amount to zł.298 million in 2004, but the net result will be negative due to weak dollar. (Puls Biznesu, pp. 1, 10) M.M.
From Warsaw Business Journal
Advertisement
back
Go to topOur partners
